Preliminary evaluation of calcium hydroxylapatite as a transurethral bulking agent for stress urinary incontinence
- PMID: 11248613
- DOI: 10.1016/s0090-4295(00)01098-0
Preliminary evaluation of calcium hydroxylapatite as a transurethral bulking agent for stress urinary incontinence
Abstract
Objectives: To evaluate the potential of calcium hydroxylapatite particles as a bulking material for the treatment of stress incontinence.
Methods: Ten women (mean age 68 years, range 60 to 82) with stress incontinence associated with intrinsic sphincter deficiency and limited hypermobility were treated with one (3 patients) or two (7 patients) injections of calcium hydroxylapatite particles and were followed up for 1 year subsequent to the last injection.
Results: The mean total volume injected was 3.9 mL. No significant safety issues were identified with regard to local pain, infection, induration, or obstruction. Seven women reported substantial improvement using many fewer pads or none at all (3 patients) at 1 year, 2 women reported fewer pads, and 1 patient reported no change. The daily mean pad use declined from 2.59 to 1.64 and the mean 24-hour pad weight declined by more than 90% (104.9 versus 1.5 g). The mean Valsalva leak point pressure (VLPP) increased from 39 to 46 cm H(2)O at 12 months, with 2 patients dry on testing.
Conclusions: The results of this small initial study suggest that calcium hydroxylapatite particles have potential as a bulking agent for the treatment of stress incontinence.
Similar articles
-
Foreign-body granuloma after injection of calcium hydroxylapatite for type III stress urinary incontinence.Obstet Gynecol. 2011 Aug;118(2 Pt 2):418-421. doi: 10.1097/AOG.0b013e3182161953. Obstet Gynecol. 2011. PMID: 21768839
-
Quality of life outcomes in peri-urethral calcium hydroxylapatite injection.Int Urogynecol J. 2016 Dec;27(12):1879-1887. doi: 10.1007/s00192-016-3053-1. Epub 2016 Jun 1. Int Urogynecol J. 2016. PMID: 27250833
-
Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence.Urology. 2007 May;69(5):876-80. doi: 10.1016/j.urology.2007.01.050. Urology. 2007. PMID: 17482925 Clinical Trial.
-
Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?Curr Urol Rep. 2006 Sep;7(5):405-13. doi: 10.1007/s11934-006-0012-2. Curr Urol Rep. 2006. PMID: 16959180 Review.
-
Two-stage management of severe postprostatectomy bladder neck contracture associated with stress incontinence.Urology. 2005 Feb;65(2):316-9. doi: 10.1016/j.urology.2004.09.014. Urology. 2005. PMID: 15708045 Review.
Cited by
-
Injectable synthetic calcium hydroxylapatite ceramic microspheres (Coaptite) for passive fecal incontinence.Tech Coloproctol. 2008 Jun;12(2):99-102. doi: 10.1007/s10151-008-0406-x. Epub 2008 Jun 10. Tech Coloproctol. 2008. PMID: 18545883
-
Treatment of stress urinary incontinence: recent developments in the role of urethral injection.Urol Res. 2003 Feb;30(6):356-62. doi: 10.1007/s00240-002-0290-1. Epub 2003 Jan 30. Urol Res. 2003. PMID: 12599014 Review.
-
Use of calcium hydroxylapatite (Radiesse) for facial augmentation.Clin Interv Aging. 2008;3(1):161-74. doi: 10.2147/cia.s2065. Clin Interv Aging. 2008. PMID: 18488886 Free PMC article. Review.
-
Three Calcium Hydroxylapatite-Based Dermal Fillers Marketed in Mexico: Comparison of Particle Size and Shape Using Electron Microscopy.J Cosmet Dermatol. 2025 Mar;24(3):e70100. doi: 10.1111/jocd.70100. J Cosmet Dermatol. 2025. PMID: 40035469 Free PMC article.
-
Changes in Dermal Thickness in Biopsy Study of Histologic Findings After a Single Injection of Polycaprolactone-Based Filler into the Dermis.Aesthet Surg J. 2019 Nov 13;39(12):NP484-NP494. doi: 10.1093/asj/sjz050. Aesthet Surg J. 2019. PMID: 30778526 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical